For metastatic colorectal and lung cancer patients, where treatment with anti-EGFR monoclonal antibodies is only effective in patients whose tumours are RAS wild type, sequencing 3 exons of KRAS and 3 exons of NRAS is required, and this will possibly also be the case for other tumour types shortly. Here, EGFR is linked to neoplasm.